Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03485014 · ClinicalTrials.gov registry record · Phase 1

Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

A Phase 1 study of Postoperative Pain Management, sponsored by Pacira Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT03485014 is a Phase 1 study of Postoperative Pain Management that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 15 participants, below the 156-participant average among 5 other Postoperative Pain Management trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03485014, a Phase 1 study of Postoperative Pain Management, has completed, sponsored by Pacira Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Primary objective: The primary objective of this study is to evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal surgery. Secondary objective: The secondary objective of this study is to evaluate the safety of EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal surgery.

Interventions

  • DRUG Exparel

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2018-04-10
Est. Completion 2019-02-12
Phase Phase 1

Sponsor

Pacira Pharmaceuticals

88 total trials

What the Registry Record Tells You About NCT03485014

The ClinicalTrials.gov registry entry for NCT03485014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 5 other Postoperative Pain Management trials with a reported enrollment target (90% lower). The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postoperative Pain Management appearing as the primary indexed condition, and to 1 intervention - of which Exparel is the first listed.

NCT03485014 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03485014 about?

NCT03485014 is a clinical study titled "Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL". Primary objective: The primary objective of this study is to evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects 12 to less than 17 years of age undergoing spinal surgery. Secondary objective: The secondary objective of this study is to evaluate the safety of EXPAREL in pediatric su...

What is the current status of trial NCT03485014?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-04-10. Estimated completion is 2019-02-12.

What conditions does trial NCT03485014 study?

This clinical trial studies the following conditions: Postoperative Pain Management.

What interventions are being tested in trial NCT03485014?

The interventions under investigation include: Exparel (DRUG).

Who is sponsoring clinical trial NCT03485014?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03485014 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain Management

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.